During the 2019 annual meeting of the American Diabetes Association (ADA), Dance Biopharm presented data from the Phase 2 Samba 04 clinical trial of Dance 501 inhaled insulin for the treatment of Type 2 diabetes demonstrating that Dance 501 had a more rapid onset of action than subcutaneous insulin lispro.
The Samba 04 study enrolled 24 Type 2 patients who were receiving insulin therapy or metformin. During the trial, patients received 12, 24 and 48 U of inhaled Dance 501 and 12, 24 and 48 U of subcutaneous insulin lispro during 6 visits 3 – 17 days apart. PD properties for Dance 501 were similar to insulin lispro with comparable time to maximum action but with faster onset of action for the inhaled insulin. Dance 501 was generally well tolerated and did not cause any observed coughing or changes in lung function.
Dance Biopharm CEO Anne Whitaker commented, “Our presentations at ADA underscore Dance’s ongoing commitment to develop innovative, patient-centric inhaled therapies that lead to improved health outcomes for people living with chronic diseases like diabetes. We are excited to present new data that further reinforce the potential of Dance 501, our inhaled preservative free human insulin, as an alternative treatment to injectable insulin for diabetes. These data demonstrate the excellent performance of our soft mist inhaler platform and emboldens us to rapidly progress the development of our pipeline of novel, soft mist biologics as treatments for severe and chronic diseases.”
Read the Dance Biopharm press release.
